Tag: 2026 guidance
-
B2Gold 2025 Results: Q4 and Full-Year Performance and 2026 Guidance
Overview B2Gold Corp. (TSX: BTO, NYSE American: BTG) is slated to release its fourth quarter and full-year 2025 financial results along with 2026 guidance in late January 2026. The announcement, coming from the Vancouver-based gold producer, is highly anticipated by investors as it will outline the company’s annual performance metrics, operating discipline, and strategic outlook…
-
B2Gold Q4 2025 Financial Results and 2026 Guidance
B2Gold to Announce Q4 2025 Results and 2026 Guidance Mining company B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) has announced that its fourth quarter and full year 2025 financial results, along with 2026 guidance, will be released after the North American market close on the scheduled date. The company, known for its diversified…
-
B2Gold Q4 2025 Results: 2026 Guidance Preview
What to Expect from B2Gold’s Q4 2025 Release B2Gold Corp. is set to publish its fourth-quarter and full-year 2025 financial results, along with 2026 guidance. As one of the andesitic growth-focused gold producers, the company’s quarterly report typically covers production volumes, all-in sustaining costs (AISC), mine-site cash costs, and capital expenditure plans for the coming…
-
SOPHiA GENETICS Reports 2025 Results, Sets 2026 Guidance, and Announces CEO Transition
Strong Q4 2025 Performance and Full-Year Results SOPHiA GENETICS, a global leader in AI-driven precision medicine, announced preliminary fourth-quarter and full-year 2025 financial results, highlighting robust momentum as the company advances its AI-powered platform across life sciences and clinical applications. While the company noted that the 2025 results are preliminary, management emphasized solid quarterly execution…
-
SOPHiA GENETICS Announces 2025 Results, 2026 Guidance, and CEO Transition Plan
Executive Summary: Strong 2025 Close and New Growth Outlook SOPHiA GENETICS (Nasdaq: SOPH) has disclosed preliminary fourth-quarter and full-year 2025 financial results, along with guidance for 2026 and a strategic executive transition. The company underscored a solid close to 2025, highlighted by robust Q4 performance, and introduced its 2026 revenue growth target of 20-22%. In…
-
SOPHiA GENETICS Reports Strong Q4 2025, Sets 2026 Growth Path and Names New CEO
SOPHiA GENETICS Announces Strong Q4 2025 Performance and Full-Year Results SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI-driven genomic analytics, released preliminary fourth-quarter and full-year 2025 results that underscore the company’s momentum as it navigates a competitive bioinformatics landscape. While the company provided preliminary numbers ahead of final audited results, executives highlighted continued revenue growth,…